Urocortin (Human)

Asp-Asn-Pro-Ser-Leu-Ser-Ile-Asp-Leu-Thr-Phe-His-Leu-Leu-Arg-Thr-Leu-Leu-Glu-Leu-Ala-Arg-Thr-Gln-Ser-Gln-Arg-Glu-Arg-Ala-Glu-Gln-Asn-Arg-Ile-Ile-Phe-Asp-Ser-Val-NH₂
: (M.W. 4696.2) C₂₀₄H₃₃₇N₆₃O₆₄
: Ligand for Type 1/Type 2 CRF Receptors

Package	Price(Yen)	Availability	Quantity
Vial 0.1 mg	14,000	Ships within 1-3 business days
バルク見積もり

Solubility: 0.1% AcOH (0.1 mM)

C.J. Donaldson, S.W. Sutton, M.H. Perrin, A.Z. Corrigan, K.A. Lewis, J.E. Rivier, J.M. Vaughan, and W.W. Vale, Endocrinology, 137, 2167 (1996). (Original; cDNA & Pharmacol.)
D.P. Behan, O. Khongsaly, N. Ling, and E.B. De Souza, Brain Res., 725, 263 (1996). (Biochem.)
Y. Murakami, T. Mori, K. Koshimura, M. Kurosaki, T. Hori, N. Yanaihara, and Y. Kato, Endocr. J., 44, 627 (1997). (Pharmacol.)
K. Takahashi, K. Totsune, M. Sone, O. Murakami, F. Satoh, Z. Arihara, H. Sasano, K. Iino, and T. Mouri, Peptides, 19, 643 (1998). (Immunohistochem.)
C.L. Chang and S.Y.T. Hsu, Peptides, 25, 1681 (2004). (Review)
E.A. Woodcock, Endocrinology, 145, 21 (2004). (Review)
Y. Kuperman and A. Chen, Trends Endocrinol. Metab., 19, 122 (2008). (Review)
W.H. Pan and A.J. Kastin, Prog. Neurobiol., 84, 148 (2008). (Review)
P. Boonprasert, N. Lailerd, and N. Chattipakorn, Int. J. Cardiol., 127, 307 (2008). (Review)